COMMUNIQUÉS West-GlobeNewswire

Considering MEDVi QUAD in 2026? Read This Before Enrolling in Any Compounded ED Telehealth Program
26/02/2026
An informational overview of publicly available disclosures, regulatory context, and verification steps consumers commonly review before starting compounded erectile dysfunction treatment through telehealth. NEWARK, DE [...]
Palvella Therapeutics Announces Pricing of Upsized Public Offering
26/02/2026
WAYNE, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat [...]
Considering MEDVi Tirzepatide GLP-1 Weight Loss in 2026? Read This Before Enrolling in Any Tirzepatide GLP-1 Telehealth Weight Loss Program
26/02/2026
An independent informational overview of MEDVi's compounded tirzepatide telehealth program, including regulatory classification, platform structure, pricing disclosures, and key consumer verification steps. NEWARK, DE, [...]
Sprout Health GLP-1 Weight Loss in 2026 — Compounded Semaglutide Pricing, FDA Status, and What To Know Before Starting a Telehealth GLP-1 Program
26/02/2026
An Independent Informational Overview Examining Sprout Health's Compounded GLP-1 Telehealth Model, Semaglutide and Tirzepatide Program Costs, FDA Regulatory Classification, and Consumer Verification Considerations for [...]
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering
26/02/2026
BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today [...]
MindRank Announces First Patient Dosed in Phase III Trial of AI-Designed Oral GLP-1 Receptor Agonist MDR-001
26/02/2026
SHANGHAI, China, Feb. 25, 2026 (GLOBE NEWSWIRE) -- MindRank, a clinical-stage artificial intelligence (AI)-empowered drug discovery company, today announced that the first patient has been dosed in the Phase III [...]
Surrozen to Present at Upcoming Healthcare Investor Conference
25/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling [...]
OraSure Announces Fourth Quarter 2025 Financial Results
25/02/2026
BETHLEHEM, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for [...]
RXSight, Inc. Reports Fourth Quarter and 2025 Results; Issues 2026 Guidance
25/02/2026
ALISO VIEJO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter and full year ended December 31, 2025. Strategic Highlights and Recent Developments [...]
Korro to Present at the TD Cowen 46th Annual Health Care Conference
25/02/2026
CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent [...]
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance
25/02/2026
Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3% FIRDAPSE ® ( [...]
NANOBIOTIX participera à plusieurs conférences investisseurs en mars
25/02/2026
PARIS et CAMBRIDGE, Mass., 25 févr. 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Société » ), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]
NANOBIOTIX to Participate in Investor Conferences in March
25/02/2026
PARIS and CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “ Company ”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand [...]
Chemed Reports Fourth-Quarter 2025 Results
25/02/2026
CINCINNATI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation [...]
ACTG Announces Publication of STOMP Results in the New England Journal of Medicine
25/02/2026
Study findings do not support routine use of tecovirimat in people with mpox CHAPEL HILL, N.C., Feb. 25, 2026 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, [...]
LENSAR® Provides Update on Pending Acquisition by Alcon
25/02/2026
ORLANDO, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, [...]
Premier Health Reports 2026 First Quarter Results
25/02/2026
MONTRÉAL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSX-V: PHA ) (the “ Company ”), a leading Canadian Healthtech company, announces it has filed its unaudited Quarterly Consolidated Financial [...]
LifeStance Health Group Announces Launch of Secondary Public Offering
25/02/2026
SCOTTSDALE, Ariz., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation’s largest providers of virtual and in-person outpatient mental health [...]
Teladoc Health Reports Fourth Quarter and Full Year 2025 Results
25/02/2026
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended December 31, 2025 (“Fourth Quarter 2025”) and [...]

Pages